From Chinese Laboratories to Global Markets: Samer Choucair Tracks the Redistribution of Drug-Innovation Returns
Investment leader Samer Choucair said the global pharmaceutical industry has entered a new phase in the pricing of innovation, as major drugmakers acquire rights to China-developed molecules at an unprecedented pace in an effort to offset approaching patent expirations and rebuild their pipelines.
Choucair said the value of China-originated licensing transactions reached roughly $138 billion in 2025, while activity remained strong through 2026. Industry tracking also indicates that China-to-West pharmaceutical licensing has accelerated sharply, with some estimates placing 2025 deal value at about $136 billion and first-quarter 2026 activity alone near $60 billion.
For Samer Choucair, the development is no longer simply another chapter in geopolitical competition. It represents a redistribution of research-and-development returns, supply-chain risk, and bargaining power between Western capital and Asian innovation.
China Is Selling “Scientific Time”
Choucair said global pharmaceutical companies are not merely buying Chinese molecules. They are effectively buying a shorter capital cycle at a time when some of the industry’s largest companies are approaching major patent expirations.
Companies including AstraZeneca, Pfizer, Bristol Myers Squibb, Merck, AbbVie, and Eli Lilly have expanded their exposure to China-developed programs across oncology, obesity, metabolic disease, and other high-growth therapeutic areas.
Over the past two decades, China has accumulated capabilities in medicinal chemistry, clinical development, biomanufacturing, and AI-assisted drug discovery. The result is a shift from being primarily associated with lower-cost pharmaceutical production to becoming an increasingly important source of globally licensable drug assets, including programs that have already progressed into clinical development.
Recent evidence underlines how significant that transformation has become. Chinese companies accounted for roughly 32% of global clinical trials in 2025, up from only 2% in 2009, according to IQVIA data cited by Reuters.
Choucair said that China now represents a substantial share of the global drug-development pipeline, while the value of out-licensing transactions from Greater China has multiplied rapidly since the beginning of the decade.
Higher Financing Costs Are Encouraging Big Pharma to Buy Innovation
Samer Choucair said prolonged periods of higher U.S. interest rates have increased financing costs for smaller biotechnology companies, narrowed the IPO window, and strengthened the incentive for large pharmaceutical companies to acquire external innovation rather than develop every program internally.
China licensing offers a particularly attractive financial structure because relatively limited upfront payments can secure access to assets whose full potential value is paid only if later clinical, regulatory, and commercial milestones are achieved.
That structure allows the buyer to defer a substantial portion of the financial risk while gaining access to programs that may already have advanced through meaningful stages of research and development.
Choucair summarized the change this way: “Companies are not buying a Chinese narrative of technological leadership. They are buying a shortcut through the capital cycle. When the patent cliff approaches, the speed at which a company can access a clinic-ready asset becomes more important than the birthplace of the molecule.”
Multibillion-Dollar Transactions
Choucair said the structure of pharmaceutical deals involving Chinese companies has also changed. Transactions are no longer limited to acquiring a single late-stage asset. They increasingly include portfolios of programs, research collaborations, technology platforms, and partial transfers of scientific know-how.
One of the clearest examples is AstraZeneca’s agreement with CSPC Pharmaceutical Group focused on obesity and related metabolic diseases. The transaction carries a potential value of up to $18.5 billion, including $1.2 billion upfront and as much as $17.3 billion in additional development, regulatory, commercialization, and sales-linked payments.
The agreement gives AstraZeneca access to multiple weight-management programs as well as advanced drug-discovery capabilities. It also illustrates how Chinese pharmaceutical licensing is expanding beyond oncology into obesity, one of the largest emerging therapeutic and consumer-health markets globally.
Choucair said other transactions involving Bristol Myers Squibb, Hengrui, Pfizer, 3SBio, Innovent, AbbVie, and RemeGen show that the opportunity set now spans oncology, bispecific antibodies, metabolic disease, and next-generation biological therapies.
The rising size of upfront payments and total deal values also suggests that high-quality Chinese assets are no longer automatically priced at what investors once regarded as an “Asian discount.”
At the same time, Choucair emphasized that headline transaction values can be misleading if viewed as guaranteed consideration. Much of the announced value remains deferred and conditional on clinical, regulatory, and commercial milestones being achieved.
Investors Are Managing Three Interconnected Portfolios
Choucair said institutional investors increasingly need to evaluate the trend across three interconnected areas: large-cap pharmaceutical companies, small and mid-cap U.S. biotechnology companies, and venture and private capital invested in life sciences.
Chinese licensing can strengthen the pipelines of major pharmaceutical groups, but it simultaneously increases their exposure to geopolitical and regulatory risks.
At the same time, every dollar allocated to a Chinese-origin asset may represent capital that is no longer available for a domestic U.S. biotech financing round, acquisition, or partnership.
New structures are also emerging in which a Chinese-developed asset is licensed into a newly established Western biotechnology company, which can later be listed publicly or acquired by a larger pharmaceutical group.
Choucair cautioned against interpreting capital flows as a definitive judgment on the scientific superiority of one ecosystem over another.
“Markets are not voting on scientific sovereignty,” he said. “They are voting on capital-allocation efficiency during a particular investment cycle.”
For Samer Choucair, the larger danger is that political intervention can suddenly reprice an asset that investors had previously treated as an ordinary commercial opportunity.
Washington Moves Closer to the Core of Pharmaceutical Innovation
Choucair said regulatory risk has moved beyond traditional concerns about the sourcing of active pharmaceutical ingredients and into the innovation process itself.
U.S. policymakers have increasingly focused on biotechnology as a strategic and national-security issue. Biotechnology provisions were incorporated into the FY2026 National Defense Authorization framework, while the Biotech Investment National Security Act of 2026 was introduced in Congress to expand scrutiny of U.S. investment involving sensitive biotechnology.
Choucair said broader restrictions could reduce the number of Western buyers available to Chinese biotech companies and therefore pressure seller valuations.
At the same time, legal uncertainty increases the discount rate investors must apply to expected future cash flows because a transaction that appears commercially viable today could later face political, regulatory, or national-security restrictions.
The risks extend beyond licensing structures. Investors must also consider genetic data, the quality and transferability of clinical evidence, cybersecurity and health-data governance, and the availability of alternative manufacturing capacity.
Choucair warned that rapid restrictions imposed without sufficient domestic alternatives could slow patient access to therapies while increasing healthcare and insurance costs.
A Different Opportunity for Saudi Arabia and the Gulf
Samer Choucair said Saudi Arabia and the Gulf should view the transformation in global biotechnology through a different investment lens.
Saudi Vision 2030 has placed pharmaceutical security, biotechnology, healthcare transformation, and industrial localization among the Kingdom’s strategic priorities, while initiatives including Lifera are aimed at expanding domestic capabilities in biomanufacturing, vaccines, and biological medicines.
Choucair said the Gulf opportunity is not to chase every Chinese licensing transaction.
Instead, he sees an opportunity to build contract manufacturing capacity, expand clinical-trial infrastructure, develop population-specific health datasets, and allocate portions of sovereign and family capital to global life sciences through specialized funds, contract development and manufacturing organizations, and digital-health platforms.
“The Gulf investor cannot remain satisfied with simply owning hospitals or distributing pharmaceuticals,” Choucair said. “Value is created at the intersection of intelligent manufacturing, clinical data, and partnerships that transfer knowledge rather than merely transferring invoices.”
Oncology, Obesity and Artificial Intelligence
Choucair said oncology remains one of the most competitive areas in pharmaceutical development, while obesity and metabolic diseases have evolved into enormous investment categories connecting healthcare with consumer behavior, retail markets, and insurance economics.
The significance of weight-management therapies is evident in deals such as AstraZeneca’s CSPC partnership and in the company’s broader push into next-generation obesity medicines. AstraZeneca has also continued advancing its own metabolic pipeline, including moving its oral GLP-1 candidate elecoglipron toward Phase III development in 2026.
Artificial intelligence can reduce the cost and time required to identify potential drug candidates and optimize molecules, Choucair said, but it cannot eliminate the requirement for human clinical trials.
That distinction helps explain why China’s scale and speed remain strategically important even in an increasingly AI-driven research environment.
AstraZeneca’s partnerships with CSPC themselves illustrate that convergence. Its collaborations include access to AI-driven molecular-design capabilities alongside conventional drug-development programs.
Choucair added that biomanufacturing and contract development services are also likely to experience partial relocation toward the United States, Europe, and Gulf markets if restrictions on certain Chinese service platforms expand.
Redrawing the Global Map of Pharmaceutical Capital
Samer Choucair said the most likely scenario through the end of the decade is not the collapse of U.S. pharmaceutical leadership, but rather the erosion of its near-monopoly on originating the next important molecule.
The United States continues to possess major advantages in regulatory infrastructure, pricing power, commercialization, and deep capital markets.
China, however, increasingly offers a combination of faster discovery, lower development costs, expanding clinical capacity, and a growing inventory of licensable assets.
The most resilient portfolio in 2026, Choucair argued, therefore requires measured exposure to large pharmaceutical companies capable of absorbing clinical and geopolitical shocks, while avoiding excessive concentration in businesses exposed to regulatory restrictions.
At the same time, long-term investors can build exposure to healthcare infrastructure and manufacturing in economies pursuing credible localization strategies, with Saudi Arabia among the markets positioned to benefit.
“Leadership in this industry is no longer a fixed geographic location,” Samer Choucair said. “It is the ability to buy scientific time at the best risk-adjusted price.”
The global pharmaceutical race, he concluded, will therefore not be decided in Washington or Beijing alone. It will increasingly be decided inside capital-allocation models that determine who finances the next generation of drug discovery.